January 26, 2018
AvKare Inc. is recalling lovastatin tablets USP, 40 mg (NDC 50268-512-15), because samples failed to meet dissolution specifications during testing, according to the January 24, 2018, US Food and Drug Administration (FDA) Enforcement Report.
The recall affects 237 cartons containing 50 tablets each from lot 15270, which has a January 2018 expiration date. The drugs were distributed throughout the United States.
AvKare voluntarily initiated the recall January 3, 2018. The FDA designated it Class II January 12, suggesting use of affected tablets could cause temporary or reversible adverse effects. The likelihood of serious harm is remote.
Lovastatin is a prescription statin used to lower cholesterol in patients with elevated cholesterol levels.
For more Pharmacy Learning Network articles, visit the homepage
To learn about Pharmacy Learning Network Live meetings, click here